Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
18
Recruiting, any sponsor type, condition "spinal muscular atrophy"
By trial status
The same filters, counted in each status. Pick one to switch.
18 trials
Showing 1 to 18, recently updated first.
Novartis PharmaceuticalsNovartis (NVS)
NCT04174157 · 700 participants (planned) · Start Sep 25, 2018 · Primary completion Jun 30, 2038
Drug: Zolgensma · For: Spinal Muscular Atrophy (SMA)
Sites: Phoenix, Arizona; Little Rock, Arkansas; Loma Linda, California · 99 sites in all
argenxargenx (ARGX)
NCT07287982 · 60 participants (planned) · Start Dec 19, 2025 · Primary completion May 28, 2029
Drug: ARGX-119 IV · For: Spinal Muscular Atrophy (SMA)
Sites: Little Rock, Arkansas; San Diego, California; Stanford, California · 46 sites in all
BiogenBiogen (BIIB)
NCT07444476 · 90 participants (planned) · Start Sep 8, 2026 · Primary completion Jun 23, 2028
Drug: Salanersen · For: Spinal Muscular Atrophy
Sites: Palo Alto, California; Boston, Massachusetts; Norfolk, Virginia · 12 sites in all
- TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07190300 · 181 participants (planned) · Start Jan 13, 2026 · Primary completion Aug 2, 2032
Drug: Tulmimetostat; Darolutamide and 3 more · For: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Sites: Birmingham, Alabama; Iowa City, Iowa; Westwood, Kansas · 31 sites in all
- A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)Pivotal-lookingRecruiting
ORIC PharmaceuticalsIndustry
NCT07723248 · 600 participants (planned) · Start Aug 3, 2026 · Primary completion Mar 2028
Drug: Rinzimetostat; Darolutamide and 2 more · For: Metastatic Castration Resistant Prostate Cancer
Sites: Glendale, California; Coral Springs, Florida; Jeffersonville, Indiana · 15 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07448610 · 36 participants (planned) · Start Aug 27, 2026 · Primary completion May 3, 2032
Drug: Onasemnogene Abeparvovec-brve · For: Spinal Muscular Atrophy
Sites: Little Rock, Arkansas; Stanford, California; Boston, Massachusetts · 6 sites in all
- A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)Pivotal-lookingRecruiting
BiogenBiogen (BIIB)
NCT07221669 · 30 participants (planned) · Start Apr 28, 2026 · Primary completion Nov 28, 2028
Drug: Salanersen · For: Muscular Atrophy, Spinal
Sites: Chicago, Illinois; Flower Mound, Texas; Norfolk, Virginia · 14 sites in all
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06147414 · 550 participants (planned) · Start Oct 23, 2024 · Primary completion May 2027
Drug: Blood sample · For: Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including; Sickle Cell Disease; Cystic Fibrosis and 12 more
Sites: Paris, France
- A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene AbeparvovecPivotal-lookingRecruiting
BiogenBiogen (BIIB)
NCT07444450 · 42 participants (planned) · Start Oct 31, 2026 · Primary completion Jul 27, 2029
Drug: Salanersen · For: Muscular Atrophy, Spinal
Sites: Flower Mound, Texas
University of FloridaAcademic, hospital or other
NCT07766980 · 20 participants (planned) · Start Jul 27, 2026 · Primary completion Dec 2028
Drug: VM100 Nutritional Supplement · For: Duchenne Muscular Dystrophy; Duchenne Disease; Muscular Dystrophy in Children and 2 more
Sites: Gainesville, Florida
Scholar Rock, Inc.Industry
NCT07047144 · 52 participants (planned) · Start Sep 15, 2025 · Primary completion Nov 2028
Drug: Apitegromab; Nusinersen and 1 more · For: Spinal Muscular Atrophy; SMA; Spinal Muscular Atrophy Type 2 and 3 more
Sites: Phoenix, Arizona; Orange, California; Palo Alto, California · 23 sites in all
BiogenBiogen (BIIB)
NCT06555419 · 78 participants (planned) · Start Jan 16, 2025 · Primary completion Sep 30, 2027
Drug: Nusinersen · For: Muscular Atrophy, Spinal
Sites: Phoenix, Arizona; Orange, California; Palo Alto, California · 21 sites in all
- Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1Recruiting
Gemma BiotherapeuticsIndustry
NCT07070999 · 22 participants (planned) · Start Jan 6, 2026 · Primary completion Dec 2028
Drug: GB221 · For: Spinal Muscular Atrophy Type I
Sites: Porto Alegre, Brazil
University of FloridaAcademic, hospital or other
NCT06290713 · 50 participants (planned) · Start Jun 5, 2024 · Primary completion Nov 2026
Drug: Tadalafil; Placebo · For: Duchenne Muscular Dystrophy; Duchenne Disease; Muscular Dystrophy and 4 more
Sites: Gainesville, Florida
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
NCT06365788 · 53 participants (planned) · Start Apr 8, 2024 · Primary completion Dec 2027
Drug: Abemaciclib; Bicalutamide · For: Triple Negative Breast Neoplasms
Sites: Antwerp, Belgium; Brussels, Belgium; Ghent, Belgium · 6 sites in all
Hospices Civils de LyonAcademic, hospital or other
NCT06321965 · 60 participants (planned) · Start Jul 24, 2024 · Primary completion Jan 24, 2029
Drug: Biocollection · For: Spinal Muscular Atrophy
Sites: Bron, France; Brest, France; Garche, France · 8 sites in all
- Adult SMA Research and Clinical HubRecruiting
Newcastle-upon-Tyne Hospitals NHS TrustAcademic, hospital or other
NCT06978985 · 600 participants (planned) · Start Jul 29, 2022 · Primary completion Apr 30, 2027
Drug: Risdiplam; Nusinersen Injectable Product · For: Spinal Muscular Atrophy (SMA)
Sites: Birmingham, United Kingdom; Bristol, United Kingdom; Cambridge, United Kingdom · 18 sites in all
Gianni SoraruAcademic, hospital or other
NCT06169046 · 90 participants (planned) · Start Apr 13, 2024 · Primary completion Jun 30, 2027
Drug: Clenbuterol; Placebo · For: Spinal and Bulbar Muscular Atrophy
Sites: Padova, Italy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.